+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Critical Limb Ischemia - Pipeline Insight, 2022

  • PDF Icon

    Clinical Trials

  • 60 Pages
  • August 2022
  • Region: Global
  • DelveInsight
  • ID: 4745367
This “Critical Limb Ischemia - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Critical Limb Ischemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Critical Limb Ischemia Understanding

Critical Limb Ischemia: Overview

Critical Limb Ischemia (CLI) is a chronic condition and the most serious form of peripheral arterial disease (PAD). It is a major global health problem with a high and growing incidence. Importantly CLI has currently, limited treatment options and has a severe impact on the patient's quality of life. CLI results from a severe blockage of the arteries in the lower limbs Symptoms include severe burning pain in the feet or toes even at rest. Complications include ulcers in the legs and feet that do not heal and commonly lead to gangrene and for which amputation of the affected limb is the only treatment option. The global amputation rate is estimated at 25% within one year of diagnosis, but vary according to the severity of the condition with rates of 11% in patients with superficial ulcers and up to 83% in patients with gangrene. In addition to limb loss, CLI is associated with a high risk of cardiovascular events, including myocardial infarction, stroke and death. The mortality risk has been reported to be as high as 20-25% within one year of diagnosis and surpasses 50% at 5 years post-diagnosis.

"Critical Limb Ischemia - Pipeline Insight, 2022" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Critical Limb Ischemia pipeline landscape is provided which includes the disease overview and Critical Limb Ischemia treatment guidelines. The assessment part of the report embraces, in depth Critical Limb Ischemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Critical Limb Ischemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Critical Limb Ischemia R&D. The therapies under development are focused on novel approaches to treat/improve Critical Limb Ischemia.

Critical Limb Ischemia Emerging Drugs Chapters

This segment of the Critical Limb Ischemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Critical Limb Ischemia Emerging Drugs

RJX: Reven Pharmaceuticals

RJX is an intravenous (IV) drug technology platform formulated to provide multimodal support to cells. The platform approach enables the company to customize treatment dosage and frequency according to different therapeutic interests. The RJX platform technology is designed to target areas of metabolic function, oxidative stress, and blood vessel control among others. In layman's terms, the company believe RJX can mimic various physiological aspects of physical exercise and in doing so, modulate the microenvironment in which cells interact with our bloodstream and ultimately affect the microenvironment within cells themselves. Nutrient, antioxidant, and electrolyte components in RJX are also expected to contribute to this “micro-environment modulation” effect. Thus, each dose of RJX is believed to present an opportunity to condition cells towards wellness.

Critical Limb Ischemia: Therapeutic Assessment

This segment of the report provides insights about the different Critical Limb Ischemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Critical Limb Ischemia

There are approx. 10+ key companies which are developing the therapies for Critical Limb Ischemia. The companies which have their Critical Limb Ischemia drug candidates in the most advanced stage, i.e. phase I include,Reven Pharmaceuticals.


The report covers around 15+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Critical Limb Ischemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Critical Limb Ischemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Critical Limb Ischemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Critical Limb Ischemia drugs.

Critical Limb Ischemia Report Insights

  • Critical Limb Ischemia Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Critical Limb Ischemia Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Critical Limb Ischemia drugs?
  • How many Critical Limb Ischemia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Critical Limb Ischemia?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Critical Limb Ischemia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Critical Limb Ischemia and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Pluristem Therapeutics
  • Reven Pharmaceuticals, Inc.
  • Helixmith
  • Caladrius Biosciences
  • BioGenCell Ltd.

  • Ixaka

Key Products

  • RJX
  • YQ23
  • JVS-100
  • NL003
  • CLBS 12
  • Apixaban
  • BGC101
  • REX-001

Table of Contents

IntroductionExecutive Summary
Critical Limb Ischemia: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Critical Limb Ischemia - Analytical Perspective
Late Stage Products (Phase III)
  • Comparative Analysis
Drug Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Drug Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
RJX: Reven Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Critical Limb Ischemia Key CompaniesCritical Limb Ischemia Key ProductsCritical Limb Ischemia- Unmet NeedsCritical Limb Ischemia- Market Drivers and BarriersCritical Limb Ischemia- Future Perspectives and ConclusionCritical Limb Ischemia Analyst ViewsCritical Limb Ischemia Key CompaniesAppendix
List of Figures
Figure 1 Total Products for Critical Limb Ischemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Pluristem Therapeutics
  • Reven Pharmaceuticals, Inc.
  • Helixmith
  • Caladrius Biosciences
  • BioGenCell Ltd.
  • Ixaka